Naturalizing activity and safety of human monoclonal antibodies against of hepatitis C virus.
CONCLUSION: The generated human monoclonal antibodies can be used to develop a potent immunotherapy that can be administrated for the post-transplantation patients to prevent the recurrence of HCV infection. Also, the monoclonal antibodies can be used to develop a vaccine against HCV.
PMID: 29036810 [PubMed - as supplied by publisher]
Source: Human Antibodies - Category: Biochemistry Tags: Hum Antibodies Source Type: research
More News: Biochemistry | Hepatitis | Hepatitis C | Hepatitis Vaccine | Immunotherapy | Kidney Transplant | Kidney Transplantation | Liver | Liver Transplant | Study | Switzerland Health | Toxicology | Transplants | Urology & Nephrology | Vaccines | Veterinary Vaccinations